Quarterly report · Q2
3341.TEDINET S100S9Q4
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥166.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥313.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥152.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥3.4bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥2.8bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥3.4bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥7.7bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.8bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥3.4bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.9bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.7bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.5bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.7bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥1.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥193.5bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥185.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥187.6bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥135.6bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥128.8bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥57.9bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥56.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥54.0bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥22.2bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥23.8bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥22.2bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.5bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥25.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥11.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥7.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥8.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥10.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥5.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥713m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥58.44 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36.38 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥148.92 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.66 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥40.62 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 29.9% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.8% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥6.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥6.7bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥3.5bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥147.6bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥147.6bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥6.0bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥4.9bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥4.9bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥14m |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥698m |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥20.5bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥167m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥173.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥166.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥6.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥6.9bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥7.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥7.0bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥3.3bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥136.2bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥136.2bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1m |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥6.0bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥9m |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥500m |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥19.2bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥12.2bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥7.0bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥396m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥159.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥152.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥7.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥6.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 513
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of long term prepaid expenses inv cf | Prior1YTDDuration | -31000000 | JPY |
| Purchase of long term prepaid expenses inv cf | CurrentYTDDuration | -32000000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1YTDDuration | -1433000000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | CurrentYTDDuration | -273000000 | JPY |
| Payments for transfer of business2 inv cf | Prior1YTDDuration | -316000000 | JPY |
| Payments for transfer of business2 inv cf | CurrentYTDDuration | -275000000 | JPY |
| Payment of loans receivable inv cf | Prior1YTDDuration | -1731000000 | JPY |
| Payment of loans receivable inv cf | CurrentYTDDuration | － | JPY |
| Collection of loans receivable inv cf | Prior1YTDDuration | 39000000 | JPY |
| Collection of loans receivable inv cf | CurrentYTDDuration | 32000000 | JPY |
| Payments for lease and guarantee deposits inv cf | Prior1YTDDuration | -623000000 | JPY |
| Payments for lease and guarantee deposits inv cf | CurrentYTDDuration | -2658000000 | JPY |
| Proceeds from collection of lease and guarantee deposits inv cf | Prior1YTDDuration | 155000000 | JPY |
| Proceeds from collection of lease and guarantee deposits inv cf | CurrentYTDDuration | 59000000 | JPY |
| Other net inv cf | Prior1YTDDuration | -36000000 | JPY |
| Other net inv cf | CurrentYTDDuration | -20000000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -7628000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -8019000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | 800000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | -2000000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YTDDuration | 12000000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYTDDuration | 5500000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -9483000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -8477000000 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -100000000 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -0 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -374000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -374000000 | JPY |
| Other net fin cf | Prior1YTDDuration | -305000000 | JPY |
| Other net fin cf | CurrentYTDDuration | -72000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | 2536000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -5425000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -4084000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -1544000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 25543000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 23770000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 21458000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 22226000000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 3091000000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 3074000000 | JPY |
| Directors compensations sga | Prior1YTDDuration | 259000000 | JPY |
| Directors compensations sga | CurrentYTDDuration | 239000000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 862000000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 856000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 110000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 103000000 | JPY |
| Provision for directors retirement benefits sga | Prior1YTDDuration | 7000000 | JPY |
| Provision for directors retirement benefits sga | CurrentYTDDuration | 9000000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 1652000000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 1306000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |